TrialA Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Trial details
- Registry ID
- NCT06682806
- Phase
- Phase 2
PRLD
Prelude Therapeutics Incorporated
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
1Trials in this database
4Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 MutationNCT06682806 | Prelude Therapeutics Incorporated | Phase 2 | Terminated | 2026-01-23Actual |
Latest recorded trial changes
A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
NCT06682806 · Prelude Therapeutics Incorporated
Actual enrollment decreased by 1 participants
− Before
7 participants (actual)
+ After
6 participants (actual)
Completion date type changed
− Before
Estimated
+ After
Actual
Primary completion date changed
− Before
Aug 2027
+ After
23 Jan 2026
Recruitment status changed
− Before
Active not recruiting
+ After
Terminated